In the future assessments of different airway clearance techniques to optimise clearance without the use of FET is essential which should include positive expiratory pressure devices (PEP) and their potential role in airway splitting alongside airway clearance.

‘It’s not easy being green’ – Suppurative lung diseases

P107 REAL-WORLD IMPACT OF ELX/TEZ/IVA ON QUALITY OF LIFE OF CHILDREN WITH CF AGED 6–11 YEARS AND PRIMARY CAREGIVERS IN THE UK: MAGNIFY, A PROSPECTIVE, OBSERVATIONAL, NON INTERVENTIONAL STUDY

1LP Thia, 1R Thursfield, 1T Lee, 1J Legg, 1A Maitra, 1DS Unquhart, 1C McKinnon, 1M Lu, 1J Liu, 1M Jennings, 1G Vega-Hernandez, 3Noah’s Ark Children’s Hospital for Wales, University Hospital of Wales, Cardiff, UK; 2Alder Hey Children’s NHS Foundation Trust, Liverpool, UK; 3Leeds Children’s Hospital, Leeds, UK; 4Southampton Children’s Hospital, Hampshire, UK; 5Royal Manchester Children’s Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, UK; 6Royal Hospital for Children and Young People, Edinburgh, UK; 7Vertex Pharmaceuticals Incorporated, Boston, US

Objective To describe the impact of ELX/TEZ/IVA on quality of life (QOL) in children and caregivers.

Methods QOL of children with CF aged 6–11 years was evaluated via caregiver proxy using the Cystic Fibrosis Questionnaire-Revised (CFQ-R). Caregivers’ QOL was self-reported using the Care-Related QOL (CarerQoL). Data were collected at 13 sites in the UK before (baseline) and every 3 (±1) months after ELX/TEZ/IVA initiation. Change from baseline was calculated as the average of all postbaseline measurements minus baseline (mean [SD]). Additionally, children and caregivers completed a single-item measure assessing overall change in CF symptoms and caregiver’s status, respectively, on a 5-level scale from ‘much better’ to ‘much worse.’

Results 27 children and 25 caregivers provided data before and after ELX/TEZ/IVA initiation. 63.0% of children were male and 66.7% were homozygous for F508del-CFTR. The mean age was 8.9 (1.8) years at ELX/TEZ/IVA initiation. Mean ppFEV1 was 94.3 (15.5) prior to initiation. Most care-givers were female (84.0%) with a mean age of 37.6 (4.2) years. Mean follow-up for children and caregivers was 124.8 (28.7) months. Mean caregiver QOL scores were 87.3 (16.9) at baseline and 91.5 (15.3) after ELX/TEZ/IVA initiation. Mean child QOL scores were 1.1 (2.0) at baseline and 0.0 (1.7) after ELX/TEZ/IVA initiation. Mean (SD) change in caregiver QOL was 4.2 (21.2) after ELX/TEZ/IVA initiation. Caregiver QOL scores increased after ELX/TEZ/IVA initiation, with the greatest mean increase in the digestion (10.7 [23.9]) and respiratory (6.2 [12.6]) domains. The respiratory domain improvement exceeded the minimal clinically important difference of 4 points. The mean CarerQoL 5D utility score components increased by 3.43 (6.38), suggesting decreased burden of care. Most children (18/27; 67%) and caregivers (17/25; 68%) reported improvement in symptoms/status on the single-item measure.

Conclusions Data suggest that both children with CF aged 6–11 years and caregivers experienced improvement in QOL and well-being following initiation of ELX/TEZ/IVA. Further study is warranted to understand the experiences of those who did not report improvement.

Please refer to page A289 for declarations of interest related to this abstract.

P108 SHORTENING ASSESSMENT OF LUNG CLEARANCE INDEX (LCI): CAN WE AVOID NEEDING TO REPEAT THE TEST THREE TIMES?

1DY Boorman, 2C MacNaughton, 3A Maitra, 4A Jones, 4F Gilchrist, 2AHorsley, 1The University of Manchester Medical School, Manchester, UK; 2Manchester University NHS Foundation Trust, Manchester, UK; 3Royal Manchester Children’s Hospital, Manchester University NHS Foundation Trust, Manchester, UK; 4Academic Department of Child Health, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK; 5Institute of Applied Clinical Sciences, Keele University, Keele, UK; 6Division of Infection, Immunity and Respiratory Medicine, The University of Manchester Faculty of Biology, Medicine and Health, Manchester, UK

Background Lung Clearance Index (LCI) is one of the most sensitive lung function tests for detection and monitoring of CF lung disease, but has not been widely adopted into clinical practice. Clinical scalability is limited by long test times, exacerbated by the need to repeat the washout test three times to produce an average. Previous studies have shown little difference between two and three repeats in LCI when looking at group means. We aimed to establish the within-patient impact on final LCI of adding a third repeat, and whether there were features of the first two measurements that could indicate or obviate the need for a third measurement.

Methods This analysis used LCI measurements collected during a prospective longitudinal study of LCI in adults and children with mild-moderate CF (FEV1>50%). We only included visits with three or more technically adequate repeat measurements.

Results Data from 708 visits and 110 subjects (n = 44 adults) were included. 138 of 846 visits with only two technically acceptable repeats were excluded. The impact of a third measurement on final LCI was small: mean (SD) change in LCI was -0.10 (2.37)% when the third measurement was added, and for >95% of measurements LCI from 2 repeats was within 5% of that from 3 repeats. Impact on FRC was similarly small: -0.18 (2.60)% change with addition of a third measurement. The impact on final LCI and FRC was not related to the repeatability of the first two LCI or FRC measurements, nor to a combination of both of these. In other words, if the first two measurements were very close together or up to 20% different, the impact of a third repeat on final LCI output was unchanged.

Conclusions If time constraints exist in routine clinical care, two measurements provide a robust approximation of the measurement that would be obtained from three repeats. However, there is no degree of repeatability of the first two measurements that can reliably obviate need for a third. To avoid loss of data on detailed quality-control review, the objective should continue to be to collect three measurements during LCI assessment.

P109 WHEN IS BURKHOLDERIA CEPACIA COMPLEX TRULY ERADICATED IN ADULTS WITH CYSTIC FIBROSIS? A 20-YEAR FOLLOW UP STUDY

1DH Tewkesbury, 2L Pollard, 1H Green, 1AHorsley, 1D Kenna, 1AM Jones, 1Manchester University NHS Foundation Trust, Manchester, UK; 2University of Manchester, Manchester, UK; 3UK Health Security Agency, London, UK

Introduction and Objectives Due to increased morbidity associated with Burkholderia cepacia complex (BCC) infection in

10.1136/thorax-2023-BTSabstracts.259

10.1136/thorax-2023-BTSabstracts.259

10.1136/thorax-2023-BTSabstracts.260

10.1136/thorax-2023-BTSabstracts.260